STOCK TITAN

LivaNova PLC - LIVN STOCK NEWS

Welcome to our dedicated news page for LivaNova PLC (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on LivaNova PLC.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LivaNova PLC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LivaNova PLC's position in the market.

Rhea-AI Summary
LivaNova PLC (Nasdaq: LIVN) will discuss its first-quarter 2024 results in a conference call on May 1, 2024. The live audiocast will be accessible on their website. Listeners can also join via telephone. A replay will be available on the website for 90 days post-call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
earnings
-
Rhea-AI Summary
LivaNova PLC (Nasdaq: LIVN) announces positive results from OSPREY clinical study on treating obstructive sleep apnea using targeted hypoglossal nerve stimulation. The study achieved a predictive outcome with over 97.5% probability of meeting primary endpoint, concluding enrollment earlier than expected. The aura6000™ Hypoglossal Nerve Stimulator System showed safety and effectiveness in subjects with moderate to severe OSA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
clinical trial
-
Rhea-AI Summary
LivaNova PLC announces the pricing of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029 in a private offering. The notes will be senior, unsecured obligations bearing interest at 2.50% per year. LivaNova expects approximately $289.3 million in net proceeds, with an option for an additional $45 million. The notes are convertible under certain conditions and may be redeemed at LivaNova's option. The company also plans to repurchase $230.0 million aggregate principal amount of its 3.00% Cash Exchangeable Senior Notes due 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
offering
Rhea-AI Summary
LivaNova PLC announces a private offering of $300 million convertible senior notes due 2029, with additional options for up to $45 million. The notes will be convertible under certain conditions and mature on March 15, 2029. LivaNova may redeem the notes under specific circumstances. The interest rate, conversion rate, and other terms will be determined later. The company expects to enter into capped call transactions to hedge potential dilution and offset cash payments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.21%
Tags
offering
-
Rhea-AI Summary
LivaNova PLC (Nasdaq: LIVN) CEO, Vladimir Makatsaria, to present at Barclays Global Healthcare Conference in Miami. The webcast will be accessible via www.livanova.com/events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
conferences
-
Rhea-AI Summary
LivaNova PLC reported strong financial results for Q4 and full-year 2023, with revenue growth across all segments. The company initiated a wind down of the Advanced Circulatory Support segment and appointed a new CEO. Revenue for Q4 2023 was $310.1 million, up 12.8% YoY, with U.S. GAAP diluted earnings per share at $0.30. Full-year 2023 revenue was $1.15 billion, up 12.9% YoY, with U.S. GAAP diluted earnings per share at $0.32. The company expects revenue growth of 4-5% for full-year 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.02%
Tags
earnings
Rhea-AI Summary
LivaNova PLC (Nasdaq: LIVN) announced the appointment of Vladimir A. Makatsaria as the new CEO, effective March 1, 2024. Makatsaria brings extensive experience from Johnson & Johnson MedTech, and the board has expressed confidence in his ability to drive the company's strategic plan and long-term growth. William Kozy will continue as the Board Chair. Makatsaria's 30-year healthcare career includes leadership roles at Johnson & Johnson and a strong track record of innovation and team building.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
none
-
Rhea-AI Summary
LivaNova PLC (Nasdaq: LIVN) to Wind Down Advanced Circulatory Support Business, Focus on Core Cardiopulmonary and Neuromodulation Units
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.89%
Tags
none
-
Rhea-AI Summary
LivaNova PLC (Nasdaq: LIVN) will host a conference call to discuss its Q4 and full-year 2023 results on February 21, 2024. The live audiocast will be accessible at www.livanova.com/events, and a replay will be available on the website for 90 days following the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
earnings
Rhea-AI Summary
LivaNova PLC (Nasdaq: LIVN) announces Bill Kozy, Interim CEO, will present at Piper Sandler Healthcare Conference in New York. The webcast will be available on www.livanova.com/events. Replay available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
conferences
LivaNova PLC

Nasdaq:LIVN

LIVN Rankings

LIVN Stock Data

3.02B
53.67M
0.53%
104.56%
6.47%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United Kingdom
20 Eastbourne Terrace

About LIVN

livanova plc is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. our advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems.at livanova, we understand the importance of bringing both clinical and economic value to our customers. we are a strong, market-leading medical technology and services company, offering a diverse product portfolio and global reach. livanova is listed on the nasdaq stock exchange under the ticker symbol “livn.” livanova has approximately 3,000 employees worldwide. we are headquartered in london (uk) and maintain a presence in more than 100 countries. livanova is a worldwide leader in advanced circulatory support, cardiopulmonary and neuromodulation, dedicated to creating meaningful products and therapies that transform lives each and every day.